DALLAS, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=36391
A video accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=36392
Continuing to innovate in the laser technology space, Lumenis' UltraPulse CO2 laser platform is considered to be the industry gold standard solution for minimally invasive proceduresfor over three decades. Featuring superior precision and high-end performance technology, the UltraPulse DUO provides surgeons with the option to easily shift between free beam and fiber energy deliveries all within the same platform. This unique energy delivery combination allows for the superior precision needed to protect delicate tissue and the extended flexibility required for targeting difficult-to-reach anatomy.
"While scanning free beam technology is the gold standard for CO2 laser surgery, ENT surgeons are often faced with patients who have access challenges to line-of-sight techniques, including the distal airway, that cannot be addressed with one single laser modality," said Paul Castellanos, M.D., Associate Professor of Surgery at the University of Alabama at Birmingham. "With the scanning free beam and fiber integration in one CO2 laser solution, only available in the UltraPulse DUO, I am able to deliver unparalleled treatments throughout the larynx and aero digestive tract with full flexibility and precision."
During oncological procedures, clean and clear margins are valued in pathology and are a key goal in today's operating room. The UltraPulse DUO generates clear margin visibility that can lead to better oncological outcomes. Patients undergoing treatment with UltraPulse DUO may benefit from fewer adverse events, such as adhesions and quicker recovery time, because of the system's capability to highly preserve adjacent delicate and healthy tissue.
As a true combination of the Digital AcuBlade™ Scanning Micromanipulator and the FiberLase™ CO2 laser fiber, the platform provides surgeons with an optimal laser solution with its short learning curve and featuring the market's only system with an adjustable aiming beam and a renewable tip.
"Lumenis is proud to introduce the UltraPulse DUO, a system developed in part with physicians, as a testament to our ongoing collaboration and commitment to surgeons and patients worldwide," said Tzipi Ozer-Armon, CEO of Lumenis. "With our commitment to enhance clinical performance and care, along with our sensitivity to our economic environment, this advanced product platform can benefit surgeons and their healthcare facilities. The UltraPulse DUO addresses multiple indications and enables ENT surgeons to extend their performance from the operating room to the outpatient environment, leading to cost savings and reduction in general anesthesia risks."
Lumenis encourages you to join our educational symposium entitled: "First DUO Experience," where four clinical experts will present their first experience with the UltraPulse DUO. The symposium will take place on Monday, September 28, 2015 between 2:00-3:00pm, at the AAO-HNSF Official Product Theater Booth #1977 in the OTO EXPO℠.
About Lumenis
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Forward-Looking Statements
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
